Palo Alto Investors LP 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-13 4:02 pm Sale | 2024-09-30 | 13G | Revance Therapeutics, Inc. RVNC | Palo Alto Investors LP | 1,611,787 1.540% | -3,625,497 (-69.22%) | Filing |
| 2024-02-14 4:55 pm Sale | 2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC | Palo Alto Investors LP | 5,237,284 5.960% | -46,325 (-0.88%) | Filing |
| 2023-02-14 4:22 pm Purchase | 2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC | Palo Alto Investors LP | 5,283,609 6.420% | 914,243 (+20.92%) | Filing |
| 2022-02-14 5:04 pm Purchase | 2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC | Palo Alto Investors LP | 4,369,366 6.090% | 4,369,366 (New Position) | Filing |